Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Debt to Equity (2022 - 2025)

Tarsus Pharmaceuticals has reported Debt to Equity over the past 4 years, most recently at $0.21 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.21 for Q4 2025, down 34.08% from a year ago — trailing twelve months through Dec 2025 was $0.21 (down 34.08% YoY), and the annual figure for FY2025 was $0.21, down 34.08%.
  • Debt to Equity for Q4 2025 was $0.21 at Tarsus Pharmaceuticals, down from $0.22 in the prior quarter.
  • Over the last five years, Debt to Equity for TARS hit a ceiling of $0.32 in Q4 2024 and a floor of $0.09 in Q2 2022.
  • Median Debt to Equity over the past 4 years was $0.16 (2023), compared with a mean of $0.18.
  • Biggest five-year swings in Debt to Equity: skyrocketed 117.17% in 2024 and later plummeted 34.08% in 2025.
  • Tarsus Pharmaceuticals' Debt to Equity stood at $0.1 in 2022, then soared by 50.25% to $0.15 in 2023, then soared by 111.38% to $0.32 in 2024, then plummeted by 34.08% to $0.21 in 2025.
  • The last three reported values for Debt to Equity were $0.21 (Q4 2025), $0.22 (Q3 2025), and $0.22 (Q2 2025) per Business Quant data.